Evidence map›Paper›PMID 41032607›Full record

ArticleScience advances2025

Enhancing mRNA therapy through iterative delivery.

Joshua Seaberg, Suresh Kumar Gulla, Jocelyn Labombarde, Ram Roy, Shailendra Kumar Dhar Dwivedi, Chao Xu, Susan Kovats, Resham Bhattacharya, Priyabrata Mukherjee

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Joshua SeabergDepartment of Pathology, University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA.ORCID 0000-0003-1158-055X
Suresh Kumar GullaDepartment of Neurosurgery, University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA.ORCID 0000-0003-4216-9640
Jocelyn LabombardeDepartment of Pathology, University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA.ORCID 0000-0002-8097-0407
Ram RoyDepartment of Pathology, University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA.
Shailendra Kumar Dhar DwivediDepartment of Obstetrics and Gynecology, University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA.ORCID 0000-0002-5410-2032
Chao XuDepartment of Biostatistics and Epidemiology, University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA.ORCID 0000-0002-3821-6187
Susan KovatsDepartment of Pathology, University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA.ORCID 0000-0001-5479-9952
Resham BhattacharyaDepartment of Obstetrics and Gynecology, University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA.ORCID 0000-0003-2523-0569
Priyabrata MukherjeeDepartment of Pathology, University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA.ORCID 0000-0002-0557-0833

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ROBERT S. MANNEL · 2018 to 2026
$27.1M
TUMOR RESISTANCE MECHANISMS TO ANTI-VEGF THERAPY IN PROSTATE CANCER (Sukyung Woo)P20GM103639 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI DHANASEKARAN, DANNY N. · 2012 to 2022
$21.3M
Normalizing aberrant metabolism in ovarian cancer by a unique drug delivery systemR01CA253391 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI BHATTACHARYA, RESHAM, MUKHERJEE, PRIYABRATA · 2021 to 2025
$1.7M
Exploiting gold nanoparticle as a probe to identify therapeutic targetsR01CA260449 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Resham Bhattacharya, Priyabrata Mukherjee · 2022 to 2026
$1.6M
NCI NIH HHS P30 CA225520NCI NIH HHS R01 CA253391NCI NIH HHS R01 CA260449NIGMS NIH HHS P20GM103639
6 · The paper itself

Abstract

Clinical translation of therapeutic messenger RNA (mRNA) technologies, particularly in solid tumors, has been limited due to unavailability of effective delivery systems. Here, we describe an mRNA delivery system that overcomes current challenges by co-encapsulating gold nanoparticles (AuNPs) and mRNA within non-ionic surfactant vehicles (NSVs) to create "Aurniosoves" (AuNSVs). Through in vitro and in vivo studies, we demonstrate that AuNSVs improve vector accumulation and uptake within the tumor, resulting in enhanced protein expression and therapeutic efficacy. Mechanistically, these effects are the result of an iterative delivery process in which AuNSVs enter cells initially through clathrin-mediated endocytosis (CME) and release AuNPs into the cytoplasm. AuNPs subsequently adsorb and inactivate cellular trafficking regulators PP2A and Rab7, producing two effects: (i) rapid entry of additional AuNSVs through activation of caveolin-mediated endocytosis (CvME) and (ii) endosomal escape through inhibited endolysosomal fusion. We propose that AuNSVs be exploited as next-generation mRNA delivery systems.

Indexed as

Drug Delivery SystemsGene Transfer TechniquesMetal NanoparticlesRNA, MessengerAnimalsCell Line, TumorEndocytosisEndosomesGoldHumansMicerab7 GTP-Binding Proteinsrab GTP-Binding ProteinsGoldrab7 GTP-Binding Proteinsrab7 GTP-binding proteins, humanrab GTP-Binding ProteinsRNA, Messenger

Identifiers

PMID41032607
PMCPMC12487881

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.